Form 4: RAPT Therapeutics Director Granted 25,000 Stock Options

RAPT Therapeutics, Inc. Director Ashley L. Dombkowski was granted 25,000 stock options with an exercise price of $7.43, vesting over three years.

Summary

• Ashley L. Dombkowski, a Director of RAPT Therapeutics, Inc., was granted 25,000 Director Stock Options.
• The options have an exercise price of $7.43 per share.
• The grant date and earliest transaction date for these options is June 21, 2025.
• The options will vest in three equal annual installments over a three-year period starting from the grant date.
• The expiration date for these options is June 21, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for aligning management incentives with shareholder value, indicating a commitment to long-term growth.

Positives

• The grant of 25,000 stock options to a director aligns management's interests with shareholder value creation.
• The options have a 10-year expiration period (until June 21, 2035), providing a long-term incentive for the director.

Future Outlook

The vesting schedule over three years indicates a long-term incentive structure for the director, aligning their future performance with the company's stock appreciation.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, like RAPT Therapeutics, to attract and retain talent and align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of 25,000 stock options to a director is a standard form of equity compensation, comparable to practices in other publicly traded biotechnology companies for incentivizing board members.
• An exercise price of $7.43, likely the market price on the grant date, is typical for incentive stock options.
• A 10-year expiration period (06/21/2025 to 06/21/2035) is a common duration for employee and director stock options in the industry.

Related Party Transactions

• The grant of 25,000 stock options to Ashley L. Dombkowski, a Director, constitutes a related party transaction as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact through improved alignment of director incentives with long-term stock performance.

Next Steps

• The options will vest in three equal annual installments starting June 21, 2025.
• The director may exercise the vested options at any time before the expiration date of June 21, 2035.

Key Dates

Recommendation

Keywords

RAPT Therapeutics, RAPT, stock options, director compensation, SEC Form 4, beneficial ownership, equity grant